BR112023004410A2 - Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças que envolvem o epitélio pigmentar retinal - Google Patents
Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças que envolvem o epitélio pigmentar retinalInfo
- Publication number
- BR112023004410A2 BR112023004410A2 BR112023004410A BR112023004410A BR112023004410A2 BR 112023004410 A2 BR112023004410 A2 BR 112023004410A2 BR 112023004410 A BR112023004410 A BR 112023004410A BR 112023004410 A BR112023004410 A BR 112023004410A BR 112023004410 A2 BR112023004410 A2 BR 112023004410A2
- Authority
- BR
- Brazil
- Prior art keywords
- group
- trifluoromethyl
- hydrogen
- therapeuticly
- prevention
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000013543 active substance Substances 0.000 title abstract 2
- 210000000981 epithelium Anatomy 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000002207 retinal effect Effects 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- -1 methoxy, ethoxy, propoxy Chemical group 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTOS E SEU USO COMO SUBSTÂNCIAS TERAPEUTICAMENTE ATIVAS NO TRATAMENTO E/OU PREVENÇÃO DE DOENÇAS QUE ENVOLVEM O EPITÉLIO PIGMENTAR RETINAL. A presente invenção refere-se a um método de tratamento e/ou prevenção de uma doença que envolve o epitélio pigmentar retinal, compreendendo a administração do composto da fórmula (I) (I) ou um sal farmaceuticamente aceitável, uma mistura racêmica, um enantiômero correspondente ou, se aplicável, um diastereômero correspondente do mesmo, em que: X é NH ou O, R11, R12 e R13 são independentemente selecionados do grupo que consiste em hidrogênio, flúor, cloro, trifluorometila, metila e difluorometóxi, A é selecionado do grupo que consiste em um resíduo de fórmula (II), (III), (IV), (V), (VI), (VII) ou (VIII) em que, "*" indica o ponto de ligação ao restante da molécula, e R2, R3, R4, R5, R2I, R3I, R4I, R5I, R2II, R3II, R4II, R5II, R2III, R3III, R4III, R5III, R2IV, R3IV, R4IV, R5IV, R2V, R3V, R4V, R5V, R2VI, R3VI, R4VI e R5VI são independentemente selecionados do grupo que consiste em hidrogênio, uma alquila linear ou ramificada tendo 1 a 3 átomos de carbono, flúor, cloro, bromo, metóxi, etóxi, propóxi, trifluorometila, 2,2,2-trifluoroetila e difluorometóxi e R6 é selecionado do grupo que consiste em hidrogênio, uma alquila linear ou ramificada tendo 1 a 3 átomos de carbono, trifluorometila, e 2,2,2-trifluoroetila.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/065,795 US11541039B2 (en) | 2020-10-08 | 2020-10-08 | Compounds and their use as therapeutically active substances in the treatment and/or reducing signs or symptoms of diseases involving the retinal pigment epithelium |
| PCT/US2021/053577 WO2022076417A1 (en) | 2020-10-08 | 2021-10-05 | New compounds and their use as therapeutically active substances in the treatment and/or prevention of diseases involving the retinal pigment epithelium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023004410A2 true BR112023004410A2 (pt) | 2023-04-11 |
Family
ID=78463962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023004410A BR112023004410A2 (pt) | 2020-10-08 | 2021-10-05 | Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças que envolvem o epitélio pigmentar retinal |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11541039B2 (pt) |
| EP (1) | EP4225441A1 (pt) |
| JP (1) | JP2023549640A (pt) |
| KR (1) | KR20230083319A (pt) |
| CN (1) | CN116323600A (pt) |
| AU (1) | AU2021358736B2 (pt) |
| BR (1) | BR112023004410A2 (pt) |
| CA (1) | CA3195037A1 (pt) |
| CL (1) | CL2023000994A1 (pt) |
| IL (1) | IL301613A (pt) |
| MX (1) | MX2023003824A (pt) |
| WO (1) | WO2022076417A1 (pt) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ595305A (en) | 2005-02-14 | 2013-06-28 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| AU2015201435B2 (en) | 2007-10-12 | 2017-02-02 | Astellas Institute For Regenerative Medicine | Improved methods of producing RPE cells and compositions of RPE cells |
| KR101994492B1 (ko) | 2011-02-25 | 2019-06-28 | 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 | 망막 색소 상피 세포 시이트의 제조 방법 |
| CN105121429B (zh) | 2012-06-28 | 2017-12-12 | 诺华股份有限公司 | 补体途径调节剂和其用途 |
| CN103656742B (zh) | 2013-11-29 | 2015-04-15 | 温州医科大学 | 功能化视网膜色素上皮细胞移植片的制备方法 |
| AU2015229381B2 (en) | 2014-03-11 | 2019-11-07 | University Of Florida Research Foundation, Inc. | Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic |
| ES2766835T3 (es) | 2015-04-16 | 2020-06-15 | Merck Patent Gmbh | Derivados de 3-(1H-bencimidazol-2-il)-1H-piridin-2-ona |
| US10807973B2 (en) | 2018-12-28 | 2020-10-20 | Endogena Therapeutics, Inc. | Compounds for use as therapeutically active substances in the treatment of retinal diseases |
-
2020
- 2020-10-08 US US17/065,795 patent/US11541039B2/en active Active
-
2021
- 2021-10-05 WO PCT/US2021/053577 patent/WO2022076417A1/en active Application Filing
- 2021-10-05 MX MX2023003824A patent/MX2023003824A/es unknown
- 2021-10-05 EP EP21801340.7A patent/EP4225441A1/en active Pending
- 2021-10-05 BR BR112023004410A patent/BR112023004410A2/pt unknown
- 2021-10-05 KR KR1020237015197A patent/KR20230083319A/ko unknown
- 2021-10-05 CA CA3195037A patent/CA3195037A1/en active Pending
- 2021-10-05 AU AU2021358736A patent/AU2021358736B2/en active Active
- 2021-10-05 JP JP2023521666A patent/JP2023549640A/ja active Pending
- 2021-10-05 IL IL301613A patent/IL301613A/en unknown
- 2021-10-05 CN CN202180066722.5A patent/CN116323600A/zh active Pending
-
2022
- 2022-11-17 US US17/988,909 patent/US11844755B2/en active Active
-
2023
- 2023-04-05 CL CL2023000994A patent/CL2023000994A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023000994A1 (es) | 2023-10-06 |
| MX2023003824A (es) | 2023-04-13 |
| US11541039B2 (en) | 2023-01-03 |
| US11844755B2 (en) | 2023-12-19 |
| JP2023549640A (ja) | 2023-11-29 |
| AU2021358736A1 (en) | 2023-04-13 |
| EP4225441A1 (en) | 2023-08-16 |
| KR20230083319A (ko) | 2023-06-09 |
| IL301613A (en) | 2023-05-01 |
| US20220110921A1 (en) | 2022-04-14 |
| CN116323600A (zh) | 2023-06-23 |
| WO2022076417A1 (en) | 2022-04-14 |
| US20230124312A1 (en) | 2023-04-20 |
| AU2021358736B2 (en) | 2024-05-09 |
| CA3195037A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2359840T5 (es) | Derivados de piridina para inhibición de estearoil-CoA-desaturasa humana | |
| CN101316833B (zh) | 作为脑啡肽酶和氨肽酶n混合抑制剂的包含二硫基的氨基酸衍生物 | |
| JP6746605B2 (ja) | オキサチアジン様化合物を作製する方法 | |
| BRPI0412761A (pt) | inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc | |
| EA017806B1 (ru) | Антимикробные соединения, их синтез и применение для лечения инфекций у млекопитающих | |
| KR890001569B1 (ko) | 피리다진의 아미노 화합물의 제조방법 | |
| WO2007122634A3 (en) | Pyrimidinediones as tyrosine kinase inhibitors | |
| DE69835877D1 (de) | Trizyklische verbindungen | |
| BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
| TW200740827A (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
| ATE279192T1 (de) | Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung | |
| EA202191075A1 (ru) | Соединения для применения в качестве терапевтически активных веществ при лечении и/или предотвращении нейроретинальных заболеваний | |
| KR950029242A (ko) | 2환-방향족 화합물, 이를 함유하는 제약 및 화장품 조성물 및 이의 용도 | |
| DE69115588D1 (de) | Benzimidazolderivate, Verfahren zu deren Herstellung und deren Anwendung als Arzneimittel | |
| BR112023004410A2 (pt) | Compostos e seu uso como substâncias terapeuticamente ativas no tratamento e/ou prevenção de doenças que envolvem o epitélio pigmentar retinal | |
| ATE420853T1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
| BR9910628A (pt) | Uso de um composto da série da benzofuroxana, composição farmacêutica, e, processos para a preparação de uma formulação parenteral e para o tratamento de um mamìfero, incluindo um ser humano, de doenças cardìacas da coronária | |
| ATE239711T1 (de) | Neue allythiopyridazinderivate und verfahren zu ihrer herstellung | |
| DE69518706T2 (de) | Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom | |
| CN105267214A (zh) | N-杂芳基苯胺类化合物作为制备抗肿瘤药物的应用 | |
| ATE211127T1 (de) | Neue carbonsäure-derivate, verfahren zur herstellung und diese verbindungen enthaltende insektizide | |
| BR112021024398A2 (pt) | Processo alternativo para a preparação de ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-di-hidropirimidin-6-il]metil]-3-oxo-5,6,8,8a-tetra-hidro-1h-imidazo[1,5-a]pirazin-2-il]-carboxílico | |
| US2793155A (en) | Anaesthetic compositions | |
| KR870006043A (ko) | 피라진유도체 그 제조방법 및 약제조성물 | |
| BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo |